PMID- 38417475
OWN - NLM
STAT- MEDLINE
DCOM- 20240402
LR  - 20240402
IS  - 1535-6280 (Electronic)
IS  - 0146-2806 (Linking)
VI  - 49
IP  - 5
DP  - 2024 May
TI  - Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus 
      and obesity.
PG  - 102489
LID - S0146-2806(24)00128-2 [pii]
LID - 10.1016/j.cpcardiol.2024.102489 [doi]
AB  - Cardiovascular disease (CVD) remains a major global health concern, and obesity 
      and diabetes mellitus have been found to be important risk factors. Tirzepatide a 
      dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like 
      peptide-1 (GLP1) receptor agonist has been shown to have cardioprotective 
      effects. Noteworthy benefits of Tirzepatide include decreased cardiovascular risk 
      factors in people with Type 2 diabetes mellitus (T2DM). In the SURPASS-4 trial, 
      tirzepatide significant decreased blood pressure, body weight, and HbA1c. 
      Furthermore, the SURMOUNT-1 trial demonstrated the effectiveness of tirzepatide 
      in reducing cardiometabolic risk factors in people with obesity without T2DM. 
      Together, the dual receptor agonism improves lipid profiles, increases insulin 
      secretion, reduces inflammation, and promotes endothelial integrity. Tirzepatide 
      shows promise as a comprehensive therapeutic option for managing cardiovascular 
      risk factors in patients with T2DM and obesity. While further studies are needed 
      to assess the long-term cardiovascular benefits, current evidence supports 
      tirzepatide's potential impact on cardiovascular health beyond its antidiabetic 
      properties.
CI  - Copyright (c) 2024 Elsevier Inc. All rights reserved.
FAU - Sardar, Muhammad Bilal
AU  - Sardar MB
AD  - Department of Cardiology, Allama Iqbal Medical College, Allama Shabbir Ahmed 
      Usmani Road, Lahore 54700, Pakistan. Electronic address: 
      bilalsardar508@gmail.com.
FAU - Nadeem, Zain Ali
AU  - Nadeem ZA
AD  - Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
FAU - Babar, Muhammad
AU  - Babar M
AD  - Department of Internal Medicine, Social Security Hospital, Faisalabad, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240228
PL  - Netherlands
TA  - Curr Probl Cardiol
JT  - Current problems in cardiology
JID - 7701802
RN  - OYN3CCI6QE (tirzepatide)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 0 (Glucagon-Like Peptide-2 Receptor)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Gastric Inhibitory Polypeptide
MH  - Obesity/complications/drug therapy
MH  - Body Weight
MH  - *Glucagon-Like Peptide-2 Receptor
OTO - NOTNLM
OT  - Obesity
OT  - T2DM
OT  - Tirzepatide
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/29 00:43
MHDA- 2024/04/02 06:46
CRDT- 2024/02/28 19:13
PHST- 2024/02/24 00:00 [received]
PHST- 2024/02/24 00:00 [accepted]
PHST- 2024/04/02 06:46 [medline]
PHST- 2024/02/29 00:43 [pubmed]
PHST- 2024/02/28 19:13 [entrez]
AID - S0146-2806(24)00128-2 [pii]
AID - 10.1016/j.cpcardiol.2024.102489 [doi]
PST - ppublish
SO  - Curr Probl Cardiol. 2024 May;49(5):102489. doi: 10.1016/j.cpcardiol.2024.102489. 
      Epub 2024 Feb 28.